Inhalation
Phase 3Small molecule
Inhalation is one of 28 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Bronchiolitis Obliterans
#DrugCompanyPhaseTrials
1Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Biaxin
AbbVieApproved
Neoral
NovartisApproved
Singulair
OOrganon and Co
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Aztreonam Lysine
GileadApproved
Pulmicort
SSalix
Approved
Foradil
ViatrisApproved
Esbriet
LLegacy Health System
Approved
Simulect
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhalation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPari Pharma GmbH